Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Carcinoma

Biliary Tract Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Biliary Tract Diseases

Gastrointestinal Diseases

Biliary Tract Cancer

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Bevacizumab

Leucovorin

Fluorouracil

Oxaliplatin

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Intervention = "bevacizumab" in combination with chemotherapy

Treatment of biliary system carcinoma using "Bevacizumab" in combination with "modified FOLFOX6".

Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay \> 4 weeks

"Bevacizumab" in combination with "modified FOLFOX6".

John L Marshall, MD

This study is for patients with biliary tract cancer that has spread and who are not candidates for surgical resection.

The purpose of this research is to determine if bevacizumab can be safely administered with Modified FOLFOX 6 and find out what effects, good and/or bad, this type of treatment has on biliary cancer.

In this study, a combination of chemotherapy, Modified FOLFOX6 and a biologic agent, bevacizumab will be tested.

Subjects on this study will receive chemotherapy and bevacizumab every 2 weeks until their disease gets worse or they are unable to tolerate treatment.

This is a single-center, open labeled, single-arm study in patients with previously untreated unresectable biliary tract cancer. This trial will follow a Simon's two-stage optimal design. For the first stage, 9 patients will be accrued. If none of the 9 patients have controlled disease with mFOLFOX6 in combination with bevacizumab, the combination will be rejected and the trial stopped. However, if at least 1 patient of the 9 (11%) respond to treatment in the first stage, then an additional 15 patients will be entered into the second stage, for a total of 24 patients in the phase II study. If 3 (13%) or more patients respond to therapy, then the combination will be considered for further investigation.

A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma

A Single-Center, Open-Labeled, Phase II Trial of Modified FOLFOX6 With Bevacizumab in Patients With Advanced Biliary System Carcinoma

Progression-free Survival is defined as the time from randomization (or study initiation) until objective tumor progression or death.

The number of patients who underwent FOLFOX dose reductions as a result of Grade 3 toxicity.

Sanofi

Georgetown University

Treatment with modified FOLFOX6 and Bevacizumab

Modified FOLFOX6 and Bevacizumab: Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay \> 4 weeks

FOLFOX6 and Bevacizumab

Age, Continuous

Sex: Female, Male

3 males; 5 females. Average age, 68.1 years.

Dr. John L Marshall

Primary outcome of 4 participants out of 8 was undetermined due to several reasons including patient refusal of further follow up.

Of the 4 patients remaining for analysis, progression free survival of 34, 26.3, 7, and 4.7 weeks was seen.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma	NCT00881504	Biliary Tract C...	"Bevacizumab" i...	18 Years -	Georgetown University
A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma	NCT00881504	Biliary Tract C...	"Bevacizumab" i...	18 Years -	Georgetown University
A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma	NCT00881504	Biliary Tract C...	"Bevacizumab" i...	18 Years -	Georgetown University

Spots Global Cancer Trial Database for "bevacizumab" in combination with "modified folfox6".